Emanuela Pasciuto
Research Subjects
Research Interests
Emanuela Pasciuto has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Liston
The Babraham Institute, Immunology Programme, Cambridge, UK
4 shared publications - Zsuzsanna Callaerts-Vegh
Laboratory of Biological Psychology, University of Leuven, Tiensestraat 102, Leuven, Belgium
3 shared publications Bart De Strooper
2 shared publications- James Dooley
Translational Immunology Laboratory, VIB, Leuven, Belgium
2 shared publications Loriana Mascali
VIB Center for Brain and Disease Research Leuven Belgium
2 shared publications- Matthew Guy Holt
Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Elsevier in Developmental Cell
- Vol. 61 (10) , 2077-2091.e9
Inducible human yolk sac myeloid progenitors model myeloid ontogeny and enable tissue-resident macrophage replacement in vivo
- 6 October 2026
- Published by Elsevier in Developmental Cell
- Vol. 61 (10) , 2077-2091.e9
Open AccessInducible human yolk sac myeloid progenitors model myeloid ontogeny and enable tissue-resident macrophage replacement in vivo
- 11 August 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (9) , 1430-1431
T cells fast-track gut signals to the brain
- 11 August 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (9) , 1430-1431
T cells fast-track gut signals to the brain
- Open Access
- 28 March 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (5)
Molecular and cognitive signatures of ageing partially restored through synthetic delivery of IL2 to the brain
Cognitive decline is a common pathological outcome during aging, with an ill‐defined molecular and cellular basis. In recent years, the concept of inflammaging, defined as a low‐grade inflammation increasing with age, has emerged. Infiltrating T cells accumulate in the brain with age and may contribute to the amplification of inflammatory cascades and disruptions to the neurogenic niche observed with age. Recently, a small resident population of regulatory T cells has been identified in the brain, and the capacity of IL2‐mediated expansion of this population to counter neuroinflammatory disease has been demonstrated. Here, we test a brain‐specific IL2 delivery system for the prevention of neurological decline in aging mice. We identify the molecular hallmarks of aging in the brain glial compartments and identify partial restoration of this signature through IL2 treatment. At a behavioral level, brain IL2 delivery prevented the age‐induced defect in spatial learning, without improving the general decline in motor skill or arousal. These results identify immune modulation as a potential path to preserving cognitive function for healthy aging.
- 28 March 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (5)
Open AccessMolecular and cognitive signatures of ageing partially restored through synthetic delivery of IL2 to the brain
Cognitive decline is a common pathological outcome during aging, with an ill‐defined molecular and cellular basis. In recent years, the concept of inflammaging, defined as a low‐grade inflammation increasing with age, has emerged. Infiltrating T cells accumulate in the brain with age and may contribute to the amplification of inflammatory cascades and disruptions to the neurogenic niche observed with age. Recently, a small resident population of regulatory T cells has been identified in the brain, and the capacity of IL2‐mediated expansion of this population to counter neuroinflammatory disease has been demonstrated. Here, we test a brain‐specific IL2 delivery system for the prevention of neurological decline in aging mice. We identify the molecular hallmarks of aging in the brain glial compartments and identify partial restoration of this signature through IL2 treatment. At a behavioral level, brain IL2 delivery prevented the age‐induced defect in spatial learning, without improving the general decline in motor skill or arousal. These results identify immune modulation as a potential path to preserving cognitive function for healthy aging.
- Top Cited PapersOpen Access
- 26 May 2022
- Published by Springer Nature in Nature Immunology
- Vol. 23 (6) , 878-891
Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation
The ability of immune-modulating biologics to prevent and reverse pathology has transformed recent clinical practice. Full utility in the neuroinflammation space, however, requires identification of both effective targets for local immune modulation and a delivery system capable of crossing the blood–brain barrier. The recent identification and characterization of a small population of regulatory T (Treg) cells resident in the brain presents one such potential therapeutic target. Here, we identified brain interleukin 2 (IL-2) levels as a limiting factor for brain-resident Treg cells. We developed a gene-delivery approach for astrocytes, with a small-molecule on-switch to allow temporal control, and enhanced production in reactive astrocytes to spatially direct delivery to inflammatory sites. Mice with brain-specific IL-2 delivery were protected in traumatic brain injury, stroke and multiple sclerosis models, without impacting the peripheral immune system. These results validate brain-specific IL-2 gene delivery as effective protection against neuroinflammation, and provide a versatile platform for delivery of diverse biologics to neuroinflammatory patients.
- 26 May 2022
- Published by Springer Nature in Nature Immunology
- Vol. 23 (6) , 878-891
Top Cited PapersOpen AccessAstrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation
The ability of immune-modulating biologics to prevent and reverse pathology has transformed recent clinical practice. Full utility in the neuroinflammation space, however, requires identification of both effective targets for local immune modulation and a delivery system capable of crossing the blood–brain barrier. The recent identification and characterization of a small population of regulatory T (Treg) cells resident in the brain presents one such potential therapeutic target. Here, we identified brain interleukin 2 (IL-2) levels as a limiting factor for brain-resident Treg cells. We developed a gene-delivery approach for astrocytes, with a small-molecule on-switch to allow temporal control, and enhanced production in reactive astrocytes to spatially direct delivery to inflammatory sites. Mice with brain-specific IL-2 delivery were protected in traumatic brain injury, stroke and multiple sclerosis models, without impacting the peripheral immune system. These results validate brain-specific IL-2 gene delivery as effective protection against neuroinflammation, and provide a versatile platform for delivery of diverse biologics to neuroinflammatory patients.
- Open Access
- 1 November 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 140 (5) , 1394-1403.e8
Cytotoxic T-lymphocyte-associated protein 4-Ig effectively controls immune activation and inflammatory disease in a novel murine model of leaky severe combined immunodeficiency
- 1 November 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 140 (5) , 1394-1403.e8
Open AccessCytotoxic T-lymphocyte-associated protein 4-Ig effectively controls immune activation and inflammatory disease in a novel murine model of leaky severe combined immunodeficiency